


Thalidomide-O-amido-C8-NH2 TFA

Cat. No.:	HY-103614
CAS No.:	1950635-16-1
Molecular Formula:	C ₂₅ H ₃₁ F ₃ N ₄ O ₈
Molecular Weight:	572.53
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 131 mg/mL (228.81 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.7466 mL	8.7332 mL	17.4663 mL
	5 mM	0.3493 mL	1.7466 mL	3.4933 mL
	10 mM	0.1747 mL	0.8733 mL	1.7466 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand -Linker Conjugates 2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

IC₅₀ & Target

Cereblon

CUSTOMER VALIDATION

-
- Bioconjug Chem. 2020 Nov 18;31(11):2564-2575.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA